KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients.Ren FailPMID 36856148PMC99804122023-Dec0.98未发现恶性肿瘤人群证据。待处理
Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial.Emerg Microbes InfectPMID 36877135PMC100268092023-Dec0.98未发现恶性肿瘤人群证据。待处理
Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial.Lancet Respir MedPMID 36958364PMC100273342023-Dec0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.J Dermatolog TreatPMID 37036183无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
Comparison of the efficacy and safety of an oral sulfate solution and 3-L polyethylene glycol on bowel preparation before colonoscopy: a phase III multicenter randomized controlled trial.Gastrointest EndoscPMID 37422241无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
OCT Grading System of Macular Infarction Predicts Vision in Participants With Central Retinal or Hemiretinal Vein Occlusion: A Secondary Analysis of SCORE2.Am J OphthalmolPMID 37544495PMC110405912023-Dec0.98未发现恶性肿瘤人群证据。待处理
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.J Am Acad DermatolPMID 37553030无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.J Thorac OncolPMID 37574132无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.J Thorac OncolPMID 37597750无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of curcumin in maintaining remission during disease-modifying antirheumatic drug withdrawal in rheumatoid arthritis at 52 weeks: a phase III double-blind, randomized placebo-controlled trial.Rheumatol IntPMID 37650921无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.Semin Arthritis RheumPMID 37660536无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial.Diabetes Obes MetabPMID 37661308无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.Breast Cancer Res TreatPMID 37676450PMC105646702023-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.Br J HaematolPMID 37691005无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).Ann Rheum DisPMID 37696589PMC106468372023-Dec0.98未发现恶性肿瘤人群证据。待处理
Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.Clin Pharmacol TherPMID 37696652无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).Ann Rheum DisPMID 37699654PMC106468452023-Dec0.98未发现恶性肿瘤人群证据。待处理
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.Diabetes Obes MetabPMID 37724698无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.Diabetes Obes MetabPMID 37732487无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial.Adv TherPMID 37770770PMC106116392023-Dec0.98未发现恶性肿瘤人群证据。待处理
Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIV.Adv TherPMID 37776478PMC106115922023-Dec0.98未发现恶性肿瘤人群证据。待处理
Association of PSA kinetics after testosterone recovery with subsequent recurrence: secondary analysis of a phase III randomized controlled trial.World J UrolPMID 37792009无 PMCID2023-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.Ann OncolPMID 37797734无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.Eur UrolPMID 37833178无 PMCID2023-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis.Clin TherPMID 37872059无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
Low-impact laparoscopy in colorectal resection-A multicentric randomised trial comparing low-pressure pneumoperitoneum plus microsurgery versus low-pressure pneumoperitoneum alone: The PAROS II trial.Colorectal DisPMID 37897108无 PMCID2023-Dec0.93干预为非药物单独策略,未满足药物干预要求。待处理
Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.Nat MedPMID 37919438PMC107190842023-Dec0.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.ESMO OpenPMID 37922691PMC107749662023-Dec0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.Lancet HaematolPMID 37922925无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.Lancet OncolPMID 37926100无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.Acta OncolPMID 37934081无 PMCID2023-Dec0.45The record describes a randomized Phase III trial in oncology (small cell lung cancer) and meets the trial design criteria, but the provided metadata (title only, no abstract) does not contain explicit signals for the required efficacy outcomes (e.g., survival, progression, recurrence). Therefore, eligibility cannot be definitively established.待处理
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.Lancet OncolPMID 37944541无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.Lancet OncolPMID 37949086无 PMCID2023-Dec0.90The trial is a randomized, phase 2/3 study of an HPV vaccine with drug intervention and original results, but its primary endpoint is immunogenicity (geometric mean titre ratio) and safety, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the criterion for a time-to-event primary/key secondary endpoint.待处理
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.Eur J CancerPMID 37976633无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir MedPMID 37979588PMC106823702023-Dec0.98未发现恶性肿瘤人群证据。待处理
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.ESMO OpenPMID 37988950PMC107749562023-Dec0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.AtherosclerosisPMID 38016401无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.Lancet HaematolPMID 38030318无 PMCID2023-Dec0.98未发现恶性肿瘤人群证据。待处理
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.Lancet OncolPMID 38039991无 PMCID2023-Dec0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.Lancet OncolPMID 38039993无 PMCID2023-Dec1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.Br J PsychiatryPMID 38108319PMC107279112023-Dec0.98未发现恶性肿瘤人群证据。待处理
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.Clin Infect DisPMID 37466374PMC106869472023-Nov-300.98未发现恶性肿瘤人群证据。待处理
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.Clin Infect DisPMID 37539715PMC106869592023-Nov-300.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.N Engl J MedPMID 37870976无 PMCID2023-Nov-300.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.Arch OsteoporosPMID 38030806PMC106871202023-Nov-300.98未发现恶性肿瘤人群证据。待处理
Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case.Radiat OncolPMID 38031125PMC106855282023-Nov-290.85The record is a quality assurance/planning benchmark case report for a phase III randomized breast cancer trial, but it does not report survival, progression, recurrence, death, or other time-to-event efficacy outcomes. It focuses solely on radiotherapy planning compliance and dose metrics.待处理
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.JAMAPMID 38015220PMC106858822023-Nov-280.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.Medicine (Baltimore)PMID 38013289PMC106813772023-Nov-240.98未发现恶性肿瘤人群证据。待处理
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.N Engl J MedPMID 37870920无 PMCID2023-Nov-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.N Engl J MedPMID 37937763无 PMCID2023-Nov-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理